Through integrating discovery-based, translational, clinical and population research, we aim to achieve new advances in treatments, vaccines, diagnostic tests and prevention strategies to address diseases of major global significance. Through this approach we are committed to achieving better health for vulnerable communities in Australia and internationally.
More than 100 scientists are working in state-of-the art labs in Melbourne, Australia, and our Healthy Mothers, Healthy Babies research lab in Kokopo, Papua New Guinea.
Latest Research Advances:
Burnet Institute researchers have created a malaria ‘Frankenstein’ to reveal secrets about the deadly species Plasmodium vivax in a major milestone to advance the development of a world-first life-saving malaria vaccine. The research team led by Professor James Beeson and Dr Damien Drew effectively tricked a different malaria species, Plasmodium falciparum, into expressing a P. vivax protein.
Vital HIV test now a reality
VISITECT® CD4 will enable those patients in rural locations to access testing more easily and does not require investment in equipment or highly technical scientific staff to operate.
Burnet Institute research has shown that meeting or even exceeding the UNAIDS 90-90-90 targets in Australia will not be enough to achieve the national and international goal of a 90-percent reduction in HIV incidence by 2030. The research was published in the journal Clinical Infectious Diseases.
Global Health Diagnostics Group:
The Group has also won a prestigious Longitude Prize Discovery Award to aid development of a laboratory-based assay into a point-of-care test to diagnose sepsis.
The health needs of Aboriginal and Torres Strait Islander (Indigenous) adolescents in Australia have been addressed directly for the first time in a landmark study led by Co-Head of Adolescent Health, Dr Peter Azzopardi, published in The Lancet.
Professor Gilda Tachedjian presented findings at a Microbiome in HIV conference in the US that a metabolite produced by bacteria in the vaginal tract could help protect women at increased risk of HIV from contracting the virus.
Malaria Epidemiology Group:
Led by Associate Professor Freya Fowkes the landmark study published in The Lancet Global Health, found that in areas transitioning from high to moderate malaria transmission, the risk of malaria causing stillbirth increased.
Research led by Dr Clovis Palmer has identified a cancer drug that can block HIV replication. The drug has the potential to become part of a functional HIV cure where replication is suppressed to the point where therapy or treatment is not required.